Anemia and acute coronary syndrome: current perspectives

Miriam Stucchi1
Silvia Cantoni2
Enrico Piccinelli3
Stefano Savonitto4
Nuccia Morici5,6
1Division of Cardiology, ASST Vimec, Italy; 2Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda Ca’ Granda, Milano, Italy; 3Health Science Department, Milano-Bicocca University, Milano, Italy; 4Division of Cardiology, A. Manzoni Hospital, Lecco, Italy; 5De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda Ca’ Granda, Milano, Italy; 6Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy

Abstract: Reference hemoglobin (Hb) values for the definition of anemia are still largely based on the 1968 WHO Scientific Group report, which established a cutoff value of <13 g/dL for adult men and <12 g/dL for adult nonpregnant women. Subsequent studies identified different normal values according to race and age. Estimated prevalence of anemia on admission in the setting of an acute coronary syndrome (ACS) is between 10% and 43% of the patients depending upon the specific population under investigation. Furthermore, up to 57% of ACS patients may develop hospital-acquired anemia (HAA). Both anemia on admission and HAA are associated with worse short- and long-term mortality, even if different mechanisms contribute to their prognostic impact. Baseline anemia can usually be traced back to preexisting disease that should be specifically investigated and corrected whenever possible. HAA is associated with clinical characteristics, medical therapy and interventional procedures, all eliciting cardiovascular adaptive response that can potentially worsen myocardial ischemia. The intrinsic fragility of anemic patients may limit aggressive medical and interventional therapy due to an increased risk of bleeding, and could independently contribute to worse outcome. However, primary angioplasty for ST elevation ACS should not be delayed because of preexisting (and often not diagnosed) anemia; delaying revascularization to allow fast-track anemia diagnosis is usually feasible and justified in non-ST-elevation ACS. Besides identification and treatment of the underlying causes of anemia, the only readily available means to reverse anemia is red blood cell transfusion. The adequate transfusion threshold is still being debated, although solid evidence suggests reserving red blood cell transfusions for patients with Hb level <8 g/dL and considering it in selected cases with Hb levels of between 8 and 10 g/dL. No evidence supports the use of iron supplements and erythropoiesis-stimulating agents in the setting of ACS.

Keywords: anemia, acute coronary syndrome, hemoglobin, red blood cell transfusion

Introduction

Anemia in the setting of acute coronary syndrome (ACS) has an established adverse prognostic value. Its impact on outcome appears to be independent of underlying causative factors – most often multiple – and time of onset, either it being preexisting the ACS or developing during hospitalization or at follow-up. In both settings, anemia has been shown to be an independent predictor of short- and long-term mortality.1–13

However, anemia must be put in perspective, keeping in mind that the main role of hemoglobin (Hb) is to provide adequate oxygen supply to body tissues. Therefore, its concentration in blood will vary according to body mass, with resultant physiological lower levels in most women.1,2 As shown in Figure 1, when considering overt anemia,
3 main determinants need to be considered: adequate erythropoiesis – that is, bone marrow function and adequate production of the specific growth factor; erythropoietin – that is, renal function – and preserved red blood cell (RBC) mass-to-plasma volume ratio – that is, hemodilution.3–8

All these pathogenetic determinants may be deranged in patients with ischemic heart disease, leading to abnormalities in Hb levels. Addressing the mechanism(s) underlying the development of anemia in a specific patient may help to correct anemia, and possibly overcome or lessen its negative prognostic impact in the setting of ACS (Figure 2).

The aim of this article is to present an overview of current evidence regarding epidemiology, pathophysiology, prognostic role and therapeutic management of anemia in patients with ACS.

Definition of anemia and clinical determinants of Hb levels

Anemia is accurately defined as an absolute decrease in RBC mass as determined by radiolabeled blood volume analysis.14 However, the definition adopted in clinical practice commonly refers to the derived parameters, Hb and hematocrit (Hct).

Reference Hb values for the definition of anemia are still largely based on the 1968 WHO Scientific Group report, which established an Hb cutoff value of <13 g/dL for adult men and <12 g/dL for adult nonpregnant women.15 This definition is more a derivative of normal distribution of Hb concentrations and observed SDs from “average”, which is assumed to be the same as “normal”. More recently, several research groups tried to redefine anemia taking into account clinical variables in order to give more accurate estimates of normal values.

In 2006, a new cutoff for anemia was suggested by Beutler and Waalen16 based on 2 large databases: the NHANES-III, the third US National Health and Nutrition Examination Survey, and the Scripps–Kaiser survey conducted in the San Diego area between 1998 and 2002. In these analyses, normal Hb levels were set taking into account not only sex but also race and age. Results showed that people of African ancestry have at least 0.5 g/dL lower Hb levels compared to Caucasians, and people >60 years of age have lower Hb levels compared with younger adults.16

The role of age in determining Hb levels was confirmed in 2008 by Patel et al who demonstrated that the mean Hb concentration in men was lower and variance was greater with each ascending age group from 50 to >80 years.17 The reasons of this variability reside in some specific characteristics of older adults, summarized in Table 1.

Our group specifically addressed the issue of anemia in elderly patients hospitalized for ACS.18 Anemia is especially frequent in this specific patient population, being detected in up to 43% of elderly patients admitted for acute heart disease,19 and its independent adverse prognostic impact is well recognized.20 Our analysis was specifically aimed at assessing the role of 2 common conditions known to be
Anemia and acute coronary syndrome

Results demonstrated that the relationship between anemia and age per se or estimated glomerular filtration rate or BMI was weak. These results stress the concept that physiological lowering of Hb levels does not necessarily translate into overt anemia. When present, even in elderly subjects with multiple comorbidities, anemia should be viewed as a marker of an underlying disease state and should be specifically investigated as such and corrected whenever possible.

Hemodilution is an additional, and often overlooked, confounding determinant of decreased Hb levels in patients affected by ACS and concomitant heart failure. When present, even in elderly subjects with multiple comorbidities, anemia should be viewed as a marker of an underlying disease state and should be specifically investigated as such and corrected whenever possible.

Table 1 Characteristics related to anemia in the elderly

- **Sarcopenia**: the reduced muscle mass lowers the peripheral oxygen demand and, therefore, causes a physiologic reduction in circulating blood mass
- **Stem cell alteration**: older patients normally have lower cellular bone marrow and hematopoietic colony-forming unit
- **Different hormone levels** (mainly sex hormone)
- **Reduced erythropoietin induction secondary to hypoxia related to renal disfunction**
- **Impaired inflammatory answer**: the slowdown catabolism of cytokine and minor anti-inflammatory action of sex hormone induce an extension of inflammatory answer also after the stimulus removal

Associated with lower Hb levels: impaired renal function and body mass index (BMI) as surrogate markers for sarcopenia. An elderly population (aged ≥75 years) admitted for non-ST elevation ACS (NSTEACS) and enrolled in the prospective Italian Elderly ACS study was analyzed. Although anemia was confirmed to be an independent predictor of mortality, even after adjustment for the most relevant covariates, our

![Figure 2 Anemia-induced compensatory mechanisms.](image-url)
the low Hb levels turned out to be linked to fluid overload in 40%–46% of patients.\textsuperscript{14,21}

**Anemia and ACS: epidemiology and prognostic impact**

**Anemia on admission**

Several studies addressed the prevalence of anemia on admission in the setting of ACS,\textsuperscript{1–8,18} with estimates varying between 10% and 43% as summarized in Table 2.

Differences in prevalence can be traced back to multiple factors related to the specific population analyzed. For example, the prevalence of anemia is higher in patients from the Middle East where disorders of Hb synthesis are more frequently found.\textsuperscript{6} Nutritional deficits may also account for higher prevalence rates.\textsuperscript{6} As already mentioned, studies focusing on elderly patients usually report the highest figures.

In both randomized trials and meta-analyses, anemia on admission is always related to worse outcome, being associated with increased mortality at different observation time points, as summarized in Table 3.\textsuperscript{3–6,9,18}

**Hospital-acquired anemia (HAA)**

HAA, defined as development of new anemia developing during hospitalization, is often observed in patients admitted for an ACS.

In the study by Salisbury et al.,\textsuperscript{10} the prevalence of HAA was investigated in a cohort of 17,676 patients with acute myocardial infarction and normal admission Hb. Applying the age-, sex- and race-specific criteria described by Beutler and Waalen,\textsuperscript{16} HAA was diagnosed in those patients whose nadir Hb level fell during hospitalization below the set diagnostic threshold for anemia. Overall prevalence of HAA was 57%, with mild (Hb >11 g/dL), moderate (Hb 9–11 g/dL) and severe HAA (Hb <9 g/dL) accounting for 37%, 15% and 5% of patients, respectively. The presence and severity of HAA were associated with most of the clinical characteristics also associated with anemia on admission, namely, age, female sex, history of cardiovascular risk factors and chronic kidney disease. Cardiogenic shock, acute renal failure and extensive use of antiplatelet and anticoagulation therapies were identified as additional, in-hospital determinants of HAA. In-hospital mortality rates differed according to the severity of HAA, with higher rates being observed in patients with either mild moderate (adjusted odds ratio [OR] 1.38, 95% CI: 1.10–1.73) or severe HAA (adjusted OR 3.39, 95% CI: 2.59–4.44) compared with not anemic patients.\textsuperscript{10}

HAA has also been associated with long-term outcome. Results in smaller cohorts of patients linked the highest in-hospital Hb drop to worse 6-month outcome in terms of mortality (adjusted HR of 1.83%, 95% CI: 1.08–3.11, \(p=0.026\)) and death/myocardial infarction (adjusted HR 1.6%, 95% CI: 1.04–2.44, \(p=0.031\)).\textsuperscript{11} One-year mortality and cardiovascular morbidity were also higher (HR 2.47, 95% CI: 1.23–4.96, \(p=0.01\)).\textsuperscript{12}

HAA that does not resolve after discharge may have adverse long-term prognostic implications. In a group of 1065 patients studied by Hasin et al.,\textsuperscript{13} anemia of any severity was present at discharge in 35% of cases. At a median follow-up of 27 months (range 12–44 months), the authors found that anemia had resolved in 15% of the patients and persisted in 19%. In 5% of the patients, new-onset anemia (defined as an Hb decrease of at least 0.5 g/dL compared to hospital discharge values) developed. Long-term outcome, defined as all-cause mortality andrehospitalization for acute heart failure, of those patients whose HAA resolved over time was similar to that of patients who were not anemic (HR 0.8, 95% CI: 0.5–1.3). Conversely, the event rates were markedly increased in those patients with either persistent (HR 1.8, 95% CI: 1.2–2.5) or new-onset (HR 1.9, 95% CI: 1.1–3.3) anemia.\textsuperscript{13}

**Table 2** Prevalence of baseline anemia in ACS studies

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>N</th>
<th>Population</th>
<th>Nation, special note</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wu et al.,\textsuperscript{1} 2001</td>
<td>78,974</td>
<td>AMI, ≥65 years old</td>
<td>USA</td>
<td>43.4%</td>
</tr>
<tr>
<td>Archbold et al.,\textsuperscript{2} 2006</td>
<td>2310</td>
<td>ACS</td>
<td>UK</td>
<td>29.7% men</td>
</tr>
<tr>
<td>Meneveau et al.,\textsuperscript{3} 2009</td>
<td>1410</td>
<td>ACS</td>
<td>France</td>
<td>27%</td>
</tr>
<tr>
<td>Tsujita et al.,\textsuperscript{4} 2010</td>
<td>3153</td>
<td>STEACS</td>
<td>Multinational</td>
<td>10.5%</td>
</tr>
<tr>
<td>Sulaiman et al.,\textsuperscript{5} 2011</td>
<td>7922</td>
<td>ACS</td>
<td>Middle East countries</td>
<td>28%</td>
</tr>
<tr>
<td>Kunadian et al.,\textsuperscript{6} 2014</td>
<td>13,032</td>
<td>NSTEACS</td>
<td>Multinational</td>
<td>16.9%</td>
</tr>
<tr>
<td>Shiraiishi et al.,\textsuperscript{7} 2014</td>
<td>1447</td>
<td>Primary PCI in AMI</td>
<td>Japan</td>
<td>25.8%</td>
</tr>
<tr>
<td>Morici et al.,\textsuperscript{8} 2014</td>
<td>637</td>
<td>NSTEACS, ≥75 years old</td>
<td>Italy</td>
<td>37.7%</td>
</tr>
<tr>
<td>Yazi et al.,\textsuperscript{9} 2017</td>
<td>1731</td>
<td>ACS</td>
<td>UK</td>
<td>26.9%</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; N, number of in-study patients; NSTEACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEACS, ST-elevation acute coronary syndrome.
Anemia and acute coronary syndrome

In the majority of patients with heart disease, anemia of chronic disease (ACD) is diagnosed. ACD is associated with a number of conditions characterized by acute or chronic immune activation,22 including heart disease, and it has also been referred to as “anemia of inflammation”.23 This specific entity should be viewed as part of the systemic inflammatory response syndrome, a first-line defensive strategy phylogenetically developed to fight microbial infections. Iron increases the virulence of most pathogens,24,25 and the release of acute-phase cytokines (tumor necrosis factor α, interleukin (IL)-1, IL-6) is associated with reduced iron availability and iron-restricted hemopoiesis,23 as shown in Table 4. In a way, anemia associated with the systemic inflammatory response syndrome can be envisioned as the price the organism has to pay to better face infection. However, if not associated with other aggravating cofactors and being part of a protective defense strategy, ACD is seldom severe and detrimental to the organism. In this perspective, the mild anemia so often found in ischemic heart disease patients may not represent a negative prognostic marker per se. Conversely, it might be viewed as a marker of a preexisting, systemic underlying disease state defining a “more fragile” patient.

In a recent survey, Mamas et al examined the correlates and associations between anemia and subsequent cardiovascular risk in a large retrospective cohort of patients presenting with ACS and found that patients with anemia had more comorbidities compared with their counterparts with normal Hb levels. Moreover, several preexisting factors were independently associated with anemia: smoking, hyperlipidemia, angina, previous myocardial infarction, previous heart failure, previous stroke, peripheral vascular disease, and so forth. The data from their survey are summarized in Table 3.

Table 3 Outcome related to baseline anemia in ACS studies

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>N</th>
<th>Population</th>
<th>Outcome</th>
<th>Investigation time</th>
<th>Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meneveau et al,2009</td>
<td>1410</td>
<td>ACS</td>
<td>Mortality</td>
<td>In-hospital</td>
<td>HR 2.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 days</td>
<td>HR 2.3</td>
</tr>
<tr>
<td>Tsujita et al,2010</td>
<td>3153</td>
<td>STEACS</td>
<td>All-cause mortality</td>
<td>1 year</td>
<td>HR 1.98 (1.05–3.73)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Major bleeding</td>
<td>1 year</td>
<td>HR 2.15 (1.43–3.24)</td>
</tr>
<tr>
<td>Sulaiman et al,2011</td>
<td>7922</td>
<td>ACS</td>
<td>Mortality</td>
<td>In-hospital</td>
<td>OR 1.71 (1.34–2.17)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 days</td>
<td>OR 1.34 (1.06–1.71)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1-year</td>
<td>OR 1.22 (1.01–1.49)</td>
</tr>
<tr>
<td>Kunadian et al,2014</td>
<td>13,032</td>
<td>NSTEACS</td>
<td>Composite ischemic event</td>
<td>In-hospital</td>
<td>RR 1.39 (1.17–1.67)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 days</td>
<td>RR 1.40 (1.20–1.62)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 year</td>
<td>RR 1.48 (1.33–1.64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mortality</td>
<td>In-hospital</td>
<td>RR 2.07 (1.31–3.26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 days</td>
<td>RR 2.23 (1.64–3.02)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 year</td>
<td>RR 2.35 (1.94–2.84)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Major bleeding</td>
<td>In-hospital</td>
<td>RR 2.20 (1.84–2.64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 days</td>
<td>RR 2.30 (1.94–2.73)</td>
</tr>
<tr>
<td>Morici et al,2014</td>
<td>637</td>
<td>NSTEACS, ≥75 years old</td>
<td>Mortality</td>
<td>1 year</td>
<td>HR 1.72 (1.14–2.60) for Hb 10–13 g/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HR 2.50 (1.35–4.57) for Hb &lt; 10 g/dL</td>
</tr>
<tr>
<td>Yazji et al,2017</td>
<td>1731</td>
<td>ACS</td>
<td>Mortality</td>
<td>1 year</td>
<td>OR 2.42 (1.40–4.16)</td>
</tr>
<tr>
<td>Lawler et al,2013</td>
<td>233,144</td>
<td>ACS</td>
<td>Mortality</td>
<td>In-hospital</td>
<td>RR 2.76 (1.94–3.92)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 days</td>
<td>RR 2.81 (1.91–4.14) HR 1.75 (1.02–3.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 year</td>
<td>RR 1.69 (1.17–2.43)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maximum (mean 18 months)</td>
<td>HR 1.63 (1.10–2.40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR 2.08 (1.70–2.55) HR 1.49 (1.23–1.81)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Re-infarction</td>
<td>Maximum (mean 18 months)</td>
<td>RR 1.25 (0.78–2.02)</td>
</tr>
</tbody>
</table>

Abbreviations: ACS, acute coronary syndrome; HR, hazard ratio; N, number of in-study patients; NSTEACS, non-ST-elevation acute coronary syndrome; OR, odds ratio; RR, relative risk; STEACS, ST-elevation acute coronary syndrome.

Table 4 Effects of inflammatory response mediated by cytokines (IL-1, IL-6, TNFα, IFNγ, TGFβ)

- Shorter half-life of red blood cells
- Antiproliferative action against endothelial progenitor cells
- Low iron availability for emopoiesis
- Reduced erithropoietin production
- Minor response of hematopoietic progenitors to stem cell factor and EPO for receptor downregulation

Prognostic impact of anemia in ACS: a pathophysiologic prospective

In the majority of patients with heart disease, anemia of chronic disease (ACD) is diagnosed. ACD is associated with a number of conditions characterized by acute or chronic immune activation,22 including heart disease, and it has also been referred to as “anemia of inflammation”.23 This specific entity should be viewed as part of the systemic inflammatory response syndrome, a first-line defensive strategy phylogenetically developed to fight microbial infections. Iron increases the virulence of most pathogens,24,25 and the release of acute-phase cytokines (tumor necrosis factor α, interleukin (IL)-1, IL-6) is associated with reduced iron availability and iron-restricted hemopoiesis,23 as shown in Table 4. In a way, anemia associated with the systemic inflammatory response syndrome can be envisioned as the price the organism has to pay to better face infection. However, if not associated with other aggravating cofactors and being part of a protective defense strategy, ACD is seldom severe and detrimental to the organism. In this perspective, the mild anemia so often found in ischemic heart disease patients may not represent
diabetes mellitus, chronic obstructive pulmonary disease, renal disease and previous coronary intervention.\(^{26}\)

A role for the systemic inflammatory response syndrome has been suggested also in reducing the capacity for vascular healing. Solomon et al found decreased levels of peripheral circulating endothelial progenitor cells in ACS patients affected by anemia on admission compared to non-anemic subjects. They hypothesize that, in addition to a preexisting inflammatory condition, the systemic effects of the inflammatory response induced by myocardial necrosis are not just limited to blunted erythroid function but also involve the ability to produce or mobilize endothelial progenitor cells by the bone marrow. This, in turn, may compromise the vascular healing capacity and contribute to poor prognosis of patients with ACS and anemia.\(^{27}\)

Anemia has been linked to worse prognosis in a number of different clinical settings. While it is still unclear whether mild anemia directly leads to poor outcomes, it is reasonable to hypothesize that it may reflect a more severe underlying systemic illness.\(^{28}\)

**Prognostic impact of anemia in ACS: the role of suboptimal treatment**

Aside from pathophysiological considerations, anemia may impact on the outcome because anemic patients may not receive guideline-recommended treatment for ACS.

This data has emerged from the Biennial Israeli ACS registry (ACSIS) which prospectively enrolled 5600 patients with ACS. Because of a perceived increased hemorrhagic risk, coronary angiography was performed less frequently in patients with anemia compared with patients without anemia (77% vs. 91%, \(p<0.001\)). Among patients with anemia who underwent coronary angiography, the majority (95%) had obstructive coronary disease, and 78% of them were triaged to revascularization. Among anemic patients, an invasive approach was associated with lower mortality at 30 days and at 1 year, with no significant excess in major bleeding.\(^{29}\) Indeed, in-hospital bleeding complications have been reduced by the almost universal use of the radial percutaneous approach to coronary intervention, as well as more selective use of GPIIb/IIIa receptor blockers and heparins.\(^{30}\)

The lack of clarity in contemporary guideline recommendations as to how patients with anemia should be treated has also affected post-discharge treatment.

In a retrospective cohort of 422,855 patients with ACS enrolled between January 2006 and December 2010 in the UK, similar rates of angiography were observed in the anemic vs. non-anemic patients. However, anemic patients were significantly less likely to be prescribed secondary prevention medications. In this large cohort study, the impact of anemia on mortality was independent and almost comparable across the ACS spectrum.\(^{26}\)

**Anemia and ACS: to treat or not to treat?**

In the complex scenario of ACS, the balance between risks and benefits of RBC transfusion is likely to be influenced by multiple factors. From a theoretical point of view, transfusing RBC increases oxygen delivery to the vulnerable myocardium, reducing ischemic symptoms, but few confirmatory data exist.\(^{31}\)

However, the ability of transfused RBC to increase oxygen delivery may be reduced because of rapid depletion of red cell nitric oxide content during storage.\(^{32}\) Moreover, while the goal of RBC transfusions is to increase the oxygen transport (\(\text{CaO}_2\)) and oxygen delivery (\(\text{DO}_2\)), the corresponding increase of Hct results in increased blood viscosity which, in turn, decreases blood flow and reduces \(\text{DO}_2\). Therefore, increasing the Hct in anemia may not correspondingly increase \(\text{DO}_2.\)\(^{33}\) RBC transfusion-related adverse events may also hamper clinical benefits, with special regard to the so-called not infectious serious hazards of transfusion, which include transfusion-related circulatory overload and, among immune-mediated adverse reactions, transfusion-related acute lung injury.\(^{34}\) A role of RBC transfusion in increasing systemic inflammation and erythrocyte slugging in capillary vessels has also been hypothesized.\(^{35}\)

Whereas the high prevalence and adverse prognostic impact of anemia in patients with ischemic heart disease are recognized, whether it deserves treatment and at which Hb cut-off level treatment needs to be implemented are still a matter of debate. This is especially true when anemia is part of the systemic inflammatory response syndrome, which is usually seldom associated with severely decreased Hb concentration.

Even if anemia results from reversible conditions, for example, vitamin or iron deficiencies and immune-mediated hemolysis, days to weeks are usually necessary for its resolution. Therefore, the only readily available treatment is RBC transfusion.

Transfusion has an established role in the setting of acute anemia, whereas its role in chronic anemia, especially of mild degree, is still controversial. A number of studies have focused on which Hb and/or Hct level should be considered the “adequate transfusion threshold” in critically ill patients or in patients undergoing surgery.\(^{36,37}\)
The debate has centered on 2 distinct transfusion strategies: one is to consider a restrictive threshold, that is, transfusion not indicated until Hb level <7–8 g/dL, and the other is to adopt a more liberal threshold, that is, transfusion not indicated until Hb level <9–10 g/dL. Most data are derived from studies including a mixed population of intensive care unit (ICU) severely ill patients, including those with cardiac disease.

In 1999, Hebert et al published the results of TRICC trial, a multicenter randomized controlled clinical trial that compared the 30-day mortality among 838 ICU critically ill patients receiving RBC transfusion according to a restrictive or a liberal strategy. The outcome was similar in the 2 groups. However, the restrictive strategy yielded significantly better results in patients younger than 55 years and in less acutely ill patients without ACS. An analysis of the subgroup with preexisting ischemic heart disease yielded opposite results, with higher mortality rates among those patients managed according to the restrictive strategy (26% vs. 21%, \( p \)-value 0.03).38

Deans et al reported a commentary about the previous study, its design and results: although the randomization to 2 relatively fixed treatment protocols was the chosen design for simplicity and power, this approach could represent a “practice misalignment” because it applied the fixed therapeutic regimens typical of a clinical trial in a therapeutic area where treatment should be rather influenced by a patient’s characteristics and comorbidities. Indeed, the overall outcomes may be influenced by a single misaligned subgroup if patients affected by ischemic heart disease, who would be usually transfused to maintain higher Hb values, were randomized to the restrictive strategy, and younger and healthier subjects received relative large volumes of RBC. Therefore, these authors suggest developing trial designs that stratify patients into comparable subgroups to help minimize the practice misalignments.39

Clinical outcomes according to 2 transfusion strategies were reviewed also by Carson et al in a meta-analysis of >12,500 patients enrolled in clinical trials conducted in surgery and ICU subjects. The results were similar to those of the TRICC trial: compared to a liberal strategy, the restrictive one was associated with lower rates of multiple adverse clinical outcomes, including 30-day mortality, myocardial infarction, cerebrovascular accident, recurrent bleeding, pneumonia or thromboembolism.40

Data on the association between blood transfusion need and outcome in European ICU patients were obtained from the SOAP study. In this prospective, multicenter, observational study, 33% of patients received RBC transfusions (mean of transfused units \( \pm \)SD: 5.0±5.8). These patients were older, were more severely ill at admission (according to SAPS II and SOFA score), had longer duration ICU stays and had higher ICU mortality rates. Although there was a direct relation between the number of blood transfusions and the mortality rate, in a multivariate Cox regression analysis including the main confounding factors (sex, age, type of admission, medical history, fluid balance, SOFA score and SAPS II), transfused patients did not have 30-day mortality rates higher than those who were not transfused.41 This concept was resumed in the related commentary: “the sicker the patient, the more likely the transfusions will be beneficial”.42

In the setting of moderate-high risk (EuroScore ≥6) cardiac surgery, Mazer et al recently compared transfusion strategies in 4806 patients. According to their data, the restrictive strategy was non-inferior to the liberal one with respect to the composite outcome of death and major disability (myocardial infarction, stroke or new-onset renal failure with dialysis). Although no significant differences were identified among the various types of cardiac procedures, the group of patients subjected to only-CABG intervention (26%) showed an advantage with the liberal approach (unadjusted OR 1.18, 95% CI: 0.79–1.75).43

A limited number of studies focused on the prognostic impact of RBC transfusion in ACS patients,44–47 and results are not uniform also in this setting.

In 2016, Docherty et al published a systematic review and meta-analysis aimed at assessing clinical outcomes for patients affected by cardiovascular disease managed with restrictive or liberal transfusions. Data were derived from 11 randomized trials enrolling 3033 patients for 30-day mortality and from 9 trials with 2609 patients for new cardiovascular events. A restrictive transfusion threshold was associated with an increased risk of ACS in patients with cardiovascular disease: (59 events/1319 patients vs. 32 events/1290 patients; risk ratio 1.78, 95% CI: 1.18–2.70, \( p = 0.01 \), \( F = 0\% \) for restrictive transfusion). This corresponds to 4.6 episodes of ACS per 100 patients when using restrictive strategies and 2.7 episodes per 100 patients when using liberal strategies. On the other end, the length of hospital stay did not differ between restrictive and liberal transfusion strategies, and no difference was observed in 30-day mortality between the 2 groups.44

According to the meta-analysis by Chatterjee et al that included more than 203,600 ACS patients, RBC transfusion was associated with an increase in all-cause mortality and recurrent infarction.45 Similar results were reported by Rao.
et al: among 24,112 subjects affected by ACS enrolled in 3 international trials, 10% of patients underwent at least 1 blood transfusion during the hospitalization, and RBC transfusion was associated with an increased hazard for 30-day death and 30-day death/MI compared with patients who did not receive transfusions.46

Different results were obtained by Alexander et al who analyzed RBC transfusion policies and outcomes across 4 distinct nadir Hct groups (Hct ≤24% vs. Hct 24.1%–27% vs. Hct 27.1%–30% vs. Hct>30%) in 44,242 patients with NSTEACS enrolled in the CRUSADE registry. RBC transfusion had a favorable impact on in-hospital mortality in patients with a nadir Hct ≤24%, whereas higher mortality rates were observed among patients with Hct >30%. RBC transfusion in patients with intermediate Hct values did not have an impact on mortality.47

The picture seems slightly different when the impact of transfusion policies on outcome is analyzed in chronic heart failure patients. The systematic literature review conducted in 2013 by Kansagara et al, which included mainly patients with chronic heart failure, did not find consistent evidence that anemia correction improves outcomes.48

Results from clinical studies were incorporated in the most recently published guidelines concerning RBC transfusion policies for critically ill patients, including those with cardiac disease.

The UK National Institute for Health and Care Excellence guideline on blood transfusion, published in November 2015, stated that the optimal transfusion threshold for patients with ongoing ACS should be 8–10 g/dL.49

Finally, the American Association of Blood Banks “Guidelines on RBC transfusion thresholds and storage” published in 201641 recommends a restrictive RBC transfusion threshold for hospitalized, hemodynamically stable adult patients, including critically ill patients, orthopedic and cardiac surgery candidates and patients with preexisting cardiovascular disease. However, these guidelines also state that the restrictive RBC transfusion threshold cannot be applied to ACS patients who are not hemodynamically stable, similar to the 2012 Cochrane review that also recommended the use of a restrictive transfusion trigger, but suggested caution in high-risk groups such as patients with ACS.30

Given the absence of solid evidence based on randomized controlled trials, it is probably reasonable to adopt RBC transfusion in patients with Hb levels <8 g/dL and to avoid it in patients with Hb levels >10 g/dL. Hb levels between 8 and 10 g/dL still represent a “gray area” in which transfusion policies need to be tailored to a specific patient’s comorbidities, and may be based on the so-called physiologic transfusion triggers, which might potentially be used to replace arbitrary Hb-based transfusion triggers to estimate the limits of an individual patient’s tolerance to anemia.

Alternatives to RBC transfusion
As in other clinical settings, for example, chronic renal failure, anemia associated with chemotherapy, the use of iron and erythropoiesis-stimulating agents (ESAs) in patients with heart disease have been considered as means to potentially reverse anemia and overcome the need for RBC transfusions.

In studies on anemia associated with chronic heart failure,48 moderate-strength evidence suggests that intravenous iron supplements improve New York Heart Association (NYHA) class, exercise tolerance (6-minute walking distance), quality of life and cardiovascular events.51,52 However, results were similar in patients with Hb levels < and >12 g/dL for the Patient Global Assessment (p-value for interaction with Hb level = 0.98), NYHA class (p-value for interaction = 0.51) and quality of-life (p-value for interaction = 0.59) outcomes. Moreover, in the setting of ACD, characterized by inhibition of iron absorption and reduction of iron mobilization, the role of iron supplements is reasonably limited and questions its use in improving outcome in anemic patients. Iron supplements are not devoid of adverse effects. Some studies have linked iron administration with oxidative stress and immunomodulatory effects.53 Increased risk of infections has also been reported.54

In animal models, ESAs were shown to have cytoprotective effects, resulting in the reduction of cellular apoptosis and infarct size, and improvement in ejection fraction.55 These results, however, were not confirmed in clinical studies, mainly involving patients with chronic heart failure. In this setting, there is high-strength evidence that ESA use has no beneficial effects on mortality, cardiovascular events and hospitalizations, while ESAs may be associated with hypertension, venous thromboembolism and even increased mortality.48

Further studies may clarify the role of ESAs in patients with preserved systolic function or in those with coronary heart disease only.

Conclusion and future prospects
Anemia is highly prevalent in the ACS setting and is associated with worse outcomes, particularly mortality. Current guidelines recommend correction of anemia <8 g/dL, except for hemodynamically unstable ACS patients who
could benefit from Hb levels between 8 and 10 g/dL. RBC transfusion is the only readily available treatment, but it is not a solution without complications. However, the question remains whether anemia has a direct causative role in worsening short- and long-term morbidity and mortality, or if it is rather a marker of a poor clinical condition.

In order to better understand the potential adverse impact of anemia per se, studies focused on selected groups of patients (STEACS vs. NSTEACS) and on specific Hb cutoffs, rather than on generic anemia definitions, could improve our understanding of the still unresolved issue of the impact of anemia in patients with cardiac disease.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


42. Vincent JL, Lelubre C. The sicker the patient, the more likely that transfusion will be beneficial. *J Thrac Dis*. 2017;9:4912–4914.


